Log in to search using one of your social media accounts:

 

Endoscopy Could Spare More Barrett's Patients From Surgery Endoscopy Could Spare More Barrett's Patients From Surgery
For patients with Barrett's esophagus, endoscopy, a recognized treatment for high-grade dysplasia, is just as effective for intramucosal carcinoma, new research shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 17, 2017 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

FDA OKs First Adjuvant Treatment for Kidney Cancer FDA OKs First Adjuvant Treatment for Kidney Cancer
Sunitinib is now approved for use after surgery in renal cell carcinoma patients who are at high risk for disease recurrence.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 16, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Pfizer receives FDA approval for SUTENT ® (sunitinib malate) as first and only adjuvant treatment for adult patients at high risk of recurrent renal cell carcinoma
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy (surgical removal of the cancerous kidney). (Source: World Pharma News)
Source: World Pharma News - November 16, 2017 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Radiotherapy No Better Than Sorafenib for Inoperable Liver Cancer Radiotherapy No Better Than Sorafenib for Inoperable Liver Cancer
Selective internal radiotherapy (SIRT) with yttrium-90 resin microspheres does not prolong survival compared to sorafenib in patients with advanced hepatocellular carcinoma not eligible for curative treatment, according to French researchers.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - November 14, 2017 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Nonalcoholic fatty liver disease increases risk of liver, colorectal, and breast cancers
(Elsevier) Nonalcoholic fatty liver disease (NAFLD) is one of the more common chronic liver diseases worldwide. It is associated with metabolic syndrome (i.e. insulin resistance and diabetes) and predisposes to cardiovascular disease. In a new study published in the Journal of Hepatology, researchers identified links not only between NAFLD and hepatocellular carcinoma (HCC), which have been well established, but also to cancers outside the liver, including colorectal and breast cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 13, 2017 Category: Cancer & Oncology Source Type: news

Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
First Avastin® (Bevacizumab) Biosimilar Candidate Recommended for European Approval THOUSAND OAKS, Calif., Nov. 10, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorization of ABP 215, a biosimilar to Avastin® (bevacizumab). ABP 215 has been recommended for approval for the treatment of certain types of cancer, including in combination with fluoropyrimidine-based chemotherapy for metastatic carcinoma of the colon or rec...
Source: Amgen News Release - November 10, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Adrenocortical Carcinoma in Children
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - November 8, 2017 Category: General Medicine Source Type: news

Emerging From Mastectomy With A Healthy Body Image Intact
For eight years, Margaret Pelikan dreaded mammograms. In 2008, she had been diagnosed with a condition called lobular carcinoma (Source: Healthy Living - The Huffington Post)
Source: Healthy Living - The Huffington Post - November 7, 2017 Category: Consumer Health News Source Type: news

Should Some Oropharyngeal Cancer Patients Skip Adjuvant Chemo, Radiation With TORS? Should Some Oropharyngeal Cancer Patients Skip Adjuvant Chemo, Radiation With TORS?
For patients with oropharyngeal squamous cell carcinoma (OPSCC) receiving transoral robotic surgery (TORS), adjuvant radiotherapy or chemoradiotherapy (CRT) should be avoided if possible, according to a long-term functional and quality-of-life (QOL) outcomes study.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - November 6, 2017 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Cancer treatment response may be affected by gut bacteria
Conclusion This early-stage study gives us some insights into factors that might influence people's responses to a specific type of cancer treatment (immunotherapy with monoclonal antibodies). The findings are of interest, but don't have any immediate implications for cancer treatment. We don't know what the conditions that required antibiotic treatment were and whether these could have affected the response to immunotherapy. We don't know whether the antibiotics themselves influenced how well the immunotherapy worked, or whether it was their effect on gut bacteria. We also don't know whether having high levels of part...
Source: NHS News Feed - November 3, 2017 Category: Consumer Health News Tags: Cancer Source Type: news

Thymoma and Thymic Carcinoma in Children
Thymoma in Children (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - November 2, 2017 Category: General Medicine Source Type: news

A squamous cell carcinoma that disproportionately affects men
Factors that drive lip squamous cell carcinomas in men. (Source: Dermatology Times)
Source: Dermatology Times - November 1, 2017 Category: Dermatology Source Type: news

Merkel Cell Carcinoma: Not Just Another Skin Cancer Merkel Cell Carcinoma: Not Just Another Skin Cancer
Merkel cell expert Paul Nghiem, MD, PhD, explains how this rare but deadly condition differs from other forms of skin cancer.Medscape Dermatology (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - October 27, 2017 Category: Pathology Tags: Dermatology Expert Interview Source Type: news

Mutation in fallopian tube lesions may help catch ovarian cancer years earlier
(University of Pennsylvania School of Medicine) Screening for tumor cells in the fallopian tubes of women at high-risk for ovarian cancer may help detect the cancer years before it develops further, suggests a new study published online this week in Nature Communications. The new study traces the origins of high-grade serous ovarian carcinoma, the most frequent type of ovarian cancer that is often diagnosed at advanced stages, back to fallopian tube lesions known as 'p53 signatures' and serous tubal intraepithelial carcinomas (STICs) that harbor the TP53 gene mutations. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 26, 2017 Category: Cancer & Oncology Source Type: news

Direct-acting Antivirals Cut Risk of Liver Cancer Direct-acting Antivirals Cut Risk of Liver Cancer
Eradicating hepatitis C virus (HCV) with direct-acting antiviral (DAA) therapy reduces the risk of hepatocellular carcinoma by 71%, according to results of a large observational study.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - October 25, 2017 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Sharing Mayo Clinic: Breast cancer patient finds answer in centralized care
Renee Hill had received opinions from other health care facilities but desperately wanted to have her medical care centralized and coordinated. "My gut was telling me Mayo was where I needed to go," she says.? When Renee Hill was diagnosed with breast cancer ? stage 3 invasive ductal carcinoma ? on her birthday in July [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 22, 2017 Category: Databases & Libraries Source Type: news

Having More CD8+ Tumor-infiltrating Lymphocytes May Boost Ovarian Cancer Survival Having More CD8+ Tumor-infiltrating Lymphocytes May Boost Ovarian Cancer Survival
In women with high-grade serous ovarian carcinomas, increasing levels of CD8+ tumor-infiltrating lymphocytes (TILs) show a robust, dose-dependent survival benefit, according to a large observational study.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - October 19, 2017 Category: Pathology Tags: Hematology-Oncology News Source Type: news

New drug successful to treat drug-resistant thyroid cancer
According to a study published inOncotarget, palbociclib, normally used in the treatment of breast cancer, can be used to treat papillary thyroid carcinomas that are resistant to vemurafenib.Medical Xpress (Source: Society for Endocrinology)
Source: Society for Endocrinology - October 19, 2017 Category: Endocrinology Source Type: news

New Study Confirms Bariatric Surgery Lowers Cancer Risk in Women New Study Confirms Bariatric Surgery Lowers Cancer Risk in Women
Bariatric surgery has again been shown to lower cancer risk in severely obese women compared with matched nonsurgical controls, primarily via a reduction in risk of obesity-specific carcinomas.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 18, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

‘ Liquid Biopsy ’ Shows Promise for Hepatocellular Carcinoma
DNA methylation markers show effectiveness for diagnosis and predicting prognosis (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 17, 2017 Category: Cancer & Oncology Tags: Gastroenterology, Internal Medicine, Oncology, Pathology, Journal, Source Type: news

What Is Papillary Urothelial Carcinoma?
Title: What Is Papillary Urothelial Carcinoma?Category: Doctor's& Expert's views on SymptomsCreated: 10/17/2017 12:00:00 AMLast Editorial Review: 10/17/2017 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 17, 2017 Category: Cancer & Oncology Source Type: news

New Guidelines a Boon for Skin Cancer Staging
(MedPage Today) -- AJCC-8 guide expands definition of T3 cutaneous squamous cell carcinoma (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - October 15, 2017 Category: Dermatology Source Type: news

Study reveals complex biology, gender differences, in kidney cancer
(University of Rochester Medical Center) A new study is believed to be the first to describe the unique role of androgens in kidney cancer, and it suggests that a new approach to treatment, targeting the androgen receptor (AR), is worth further investigation. The study shows that in renal cell carcinoma androgen signaling can either stimulate or suppress tumor cells' movement and invasion to different locations in the body. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 13, 2017 Category: Cancer & Oncology Source Type: news

Hyalinizing Clear Cell Carcinoma of the Lung: Case Report Hyalinizing Clear Cell Carcinoma of the Lung: Case Report
Learn the key morphologic features of pulmonary hyalinizing clear cell carcinoma in this unusual case.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Liquid biopsy may be new way to detect liver cancer earlier, easier
(University of California - San Diego) An international team of researchers at University of California San Diego School of Medicine and Moores Cancer Center, with colleagues at Sun Yet-sun University Cancer Center and other collaborating institutions, have developed a new diagnostic and prognosis method for early detection of hepatocellular carcinoma (HCC), based on a simple blood sample containing circulating tumor DNA. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 9, 2017 Category: International Medicine & Public Health Source Type: news

September ’s top stories: Australia’s Zero Childhood Cancer trial, Eisai & Ono ’s liver cancer trial
Australian cancer centres launched a clinical trial under the Zero Childhood Cancer programme for personalised medicine, and Eisai and Ono Pharmaceutical planned to conduct a Phase Ib combination trial for hepatocellular carcinoma (HCC). Drugdevelopm … (Source: Drug Development Technology)
Source: Drug Development Technology - October 5, 2017 Category: Pharmaceuticals Source Type: news

Sunitinib Has No Survival Benefit in Renal-cell Carcinoma, May Limit Late Recurrence Sunitinib Has No Survival Benefit in Renal-cell Carcinoma, May Limit Late Recurrence
Adjuvant treatment of renal-cell carcinoma (RCC) after nephrectomy with sunitinib has produced no increase in overall survival, but the treatment results in less distant disease recurrence and a higher rate of disease-free survival, according to the latest data from the S-TRAC study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 5, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Outcomes After Curative Treatments of HCV-Related HCC Outcomes After Curative Treatments of HCV-Related HCC
What does the available evidence tell us about the recurrence and survival rates of HCV-related hepatocellular carcinoma after curative resection or ablation?Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 5, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Subtyping Hepatocellular Adenomas in Routine Practice Subtyping Hepatocellular Adenomas in Routine Practice
This study demonstrated that two specific subtypes of hepatocellular carcinoma can be diagnosed using only a limited immunohistochemical panel that is widely available in clinical practice.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 4, 2017 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Eisai reports positive Phase III trial data of Lenvima for liver cancer
Eisai has reported positive results from analysis of the subpopulation of subjects in the Greater China region participating in its Phase III REFLECT clinical trial of lenvatinib mesylate (Lenvima) to treat unresectable hepatocellular carcinoma (HCC) … (Source: Drug Development Technology)
Source: Drug Development Technology - October 2, 2017 Category: Pharmaceuticals Source Type: news

Quantitative Imaging Predicts Microvascular Invasion in Hepatocellular Carcinoma Quantitative Imaging Predicts Microvascular Invasion in Hepatocellular Carcinoma
Quantitative image analysis of preoperative CT scans can be used to predict microvascular invasion in patients with hepatocellular carcinoma (HCC), researchers report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 29, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

US FDA agrees to review Eisai ’s application for Lenvima to treat HCC
The US Food and Drug Administration (FDA) has agreed to review Eisai ’s application for an additional indication of Lenvima (lenvatinib mesylate) as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 27, 2017 Category: Pharmaceuticals Source Type: news

Your NEJM Group Today: Squamous Cell Carcinoma of the Mouth / Asthma Treatments Compared / California Family Medicine Opportunity (FREE)
By the Editors Take a look at today's offering from NEJM Group:NEJM Clinical Practice Center: Image in Clinical Medicine: A 54-year-old woman who regularly chewed … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 27, 2017 Category: Primary Care Source Type: news

Medical News Today: Carcinoma in situ: What is it and how is it treated?
In this article, learn about carcinoma in situ. What is carcinoma in situ and where does it occur? How is it most effectively treated? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 26, 2017 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Nivolumab Approved for Liver Cancer Nivolumab Approved for Liver Cancer
The FDA has approved the immunotherapy for use in patients with hepatocellular carcinoma who have previously been treated with sorafenib.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 25, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Bristol-Myers Squibb ’s Opdivo (nivolumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma Patients Previously Treated with Sorafenib
PRINCETON, N.J.--(BUSINESS WIRE) September 22, 2017 --Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection for intravenous use for the treatment of patients... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 22, 2017 Category: Drugs & Pharmacology Source Type: news

Medical News Today: Papillary urothelial carcinoma: Treatment and outlook
What is papillary urothelial carcinoma? What are the signs of papillary urothelial carcinoma, what are the causes, and what are the risk factors? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 21, 2017 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
First approved immunotherapy for rare and aggressive skin cancer in the European Union, with initial launches planned in Germany and the UK Builds on Bavencio's previous accelerated approvals in the US and recent approval in Switzerland Approval base... Biopharmaceuticals, Oncology, Regulatory Merck KGaA, Pfizer, BAVENCIO, avelumab, Merkel cell carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 21, 2017 Category: Pharmaceuticals Source Type: news

Merck KGaA, Pfizer's cancer drug Bavencio gets EU nod
FRANKFURT (Reuters) - European regulators on Thursday granted market approval for Merck KGaA and Pfizer's immuno-oncology drug Bavencio to treat a rare and aggressive type of skin cancer called Merkel cell carcinoma. (Source: Reuters: Health)
Source: Reuters: Health - September 21, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

More Than Okay to Reduce Sorafenib Dose for Liver Cancer More Than Okay to Reduce Sorafenib Dose for Liver Cancer
Initially reducing the dosage of the oral therapy did not compromise overall survival in hepatocellular carcinoma and had important benefits.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 15, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Tailored Treatment for Head-and-Neck Cancer Mystery
Treatment TermsHead and Neck Cancer Overview Rob Vaughn found a lump on his neck that turned out to be cancer that had spread from somewhere else in his body. The trouble was, doctors couldn ’t find the original site of the cancer. That made his treatment decisions difficult -- until two Duke specialists offered him options, including the option for watchful waiting instead of extensive treatment. Hero Image20170914_robvaughn_neckcancer_083_herocrop.jpg Preview Image Content Blocks Header A Search for the Source of Cancer ContentVaughn, a Charlotte, NC, father of two, was 47 and in good health when he felt th...
Source: dukehealth.org: Duke Health News - September 15, 2017 Category: Consumer Health News Authors: mf205 at duke.edu Source Type: news

Adrenocortical Carcinoma
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - September 14, 2017 Category: General Medicine Source Type: news

Is There a Standard for Surgical Therapy of HCC? Is There a Standard for Surgical Therapy of HCC?
This study compared different guidelines regarding indication for resection and transplantation in patients with hepatocellular carcinoma, with and without underlying cirrhosis. Is there a consensus?BMJ Open Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 13, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Eisai reports positive data from Phase Ib/II study of lenvatinib for RCC
Eisai has reported positive interim results from a Phase Ib/II clinical trial (Study 111) of Kisplyx (lenvatinib) in combination with Merck ’s anti-PD-1 therapy pembrolizumab (Keytruda) to treat patients with advanced renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - September 11, 2017 Category: Pharmaceuticals Source Type: news

Regeneron and Sanofi receive FDA ’s breakthrough therapy status for CSCC treatment with cemiplimab
US-based Regeneron Pharmaceuticals and French company Sanofi have received breakthrough therapy designation status for cemiplimab (REGN2810) from the US Food and Drug Administration (FDA) to treat cutaneous squamous cell carcinoma (CSCC). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 10, 2017 Category: Pharmaceuticals Source Type: news

Sanofi and Regeneron announce that cemiplimab (REGN2810) has received FDA Breakthrough Therapy designation for advanced cutaneous squamous cell carcinoma
Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation status to cemiplimab (REGN2810) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) and adults with locally advanced and unresectable CSCC, the second deadliest skin cancer after melanoma[1], [2]. Cemiplimab is an investigational human, monoclonal antibody targeting PD-1. (Source: World Pharma News)
Source: World Pharma News - September 8, 2017 Category: Pharmaceuticals Tags: Featured Sanofi Business and Industry Source Type: news

Regeneron and Sanofi Announce Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma
TARRYTOWN, N.Y. and PARIS, Sept. 8, 2017 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation s... Biopharmaceuticals, Oncology Regeneron Pharmaceuticals, Sanofi, cemiplimab, cutaneous squamous cell carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 8, 2017 Category: Pharmaceuticals Source Type: news

Hepatocellular carcinoma: Resection vs. transplantation
(Deutsches Aerzteblatt International) Liver transplantation is the gold standard for treating early hepatocellular cancers. Because of the lack of donors, this option is, however, available to a limited degree only. Curative liver resection is an alternative in this setting. Markus B. Schoenberg, Julian N. Bucher, and coauthors investigated whether liver resection can yield results that are comparable to those of liver transplantation. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 8, 2017 Category: Cancer & Oncology Source Type: news

Unrelenting NHS pressure affecting cancer care, say GPs and nurses
Half of GPs and primary care nurses not confident NHS workforce can provide adequate care Related items fromOnMedica Nasopharyngeal carcinoma and sinus cancer UK spends 20% less on cancer treatment than rest of EU Fifteen local NHS transformation projects to get cash boost The genetics of breast cancer Meeting cancer promises and more – a new model for NHS diagnostics? (Source: OnMedica Latest News)
Source: OnMedica Latest News - September 8, 2017 Category: UK Health Source Type: news